

**Tissue Regenix Group plc**  
(‘Tissue Regenix’ or ‘the Group’)

**Grant of share options**

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, have each been granted on 17 July 2024 an award of restricted share units ("RSUs") and Kirsten Lund EMEA Business Director a Conditional Share Award (CSA) with respect to ordinary shares in the capital of the Company ("Ordinary Shares") under the existing annual Tissue Regenix Share Incentive Plan following the publication of the 2024 trading update.

Daniel Lee has been awarded 175,743 RSUs and David Cocke has been awarded 136,353 RSUs and Kirsten Lund has been awarded 49,798 Conditional Awards, where each RSU/CSA that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs is 0.1p per Ordinary Share. The RSUs/CSA are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets.

Following the grant of these options, Daniel Lee and David Cocke hold options over a total of 649,425 and 503,865 RSUs respectively representing 0.9% and 0.7% of the current issued share capital respectively. Kirsten Lund holds options over a total of 185,796 CSA representing 0.3% of the current issued share capital.

**For more information:**

**Tissue Regenix Group plc**  
Daniel Lee, Chief Executive Officer  
David Cocke, Chief Financial Officer

[www.tissueregenix.com](http://www.tissueregenix.com)  
via Walbrook PR

**Cavendish Capital Markets Limited (Nominated Adviser and Broker)**  
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance  
Nigel Birks/Harriet Ward - ECM

**Walbrook PR (Financial PR and IR)**  
Charlotte Edgar / Alice Woodings

Tel: +44 (0)20 7933 8780  
TissueRegenix@walbrookpr.com

*The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation 'MAR' EU no.596/2014. Upon the publication of this announcement via the Regulatory Information Service 'RIS', this inside information is now considered to be in the public domain.*

**About Tissue Regenix ([www.tissueregenix.com](http://www.tissueregenix.com))**

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.**

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Daniel Lee
2	Reason for the notification	
a)	Position/status	CEO
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJ136
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each	

	<b>type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p
b)	Identification code	GB00B5SGVL29
c)	Nature of the transaction	Issue of options
d)	Price(s) and volume(s)	Volume(s): 175,743 RSUs Price: 0.1 pence per RSU
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transactions	17 July 2024
f)	Place of the transaction	Outside of a trading venue

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	David Cocke
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	CFO
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p
b)	Identification code	GB00B5SGVL29
c)	Nature of the transaction	Issue of options
d)	Price(s) and volume(s)	Volume(s): 136,353 RSUs Price: 0.1 pence per RSU
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transactions	17 July 2024
f)	Place of the transaction	Outside of a trading venue

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Kirsten Lund
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	EMEA Business Director
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36

4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Conditional Share awards with respect to ordinary shares in the capital of the Company of 0.1p
b)	Identification code	GB00B5SGVL29
c)	Nature of the transaction	Issue of options
d)	Price(s) and volume(s)	Volume(s): 49,798 CSAs Price: 0.1 pence per SCA
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transactions	17 July 2024
f)	Place of the transaction	Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHQKFBQQBKDFOD